Supplementary Material for: Clinical impact of molecular tumor board inclusion on treatmen

87 patients with rare neuroendocrine neoplasms were discussed at Molecular Tumor Boards in Freiburg and Munich between 2019 and 2024. The dataset likely contains clinical characteristics, molecular profiling results, therapy recommendations, and survival outcomes for these patients. This supplementary material was authored by a figshare admin for Karger and is licensed for reuse under CC-BY-4.0.

Use Cases

• Analyzing the association between molecular alterations and therapy recommendations based on MTB discussions
• Modeling overall survival outcomes for patients receiving MTB-guided therapy using the described landmark approach
• Studying the implementation rate of actionable therapy recommendations in a clinical setting
• Investigating the clinical impact of specific molecular pathways like DNA damage repair in neuroendocrine tumors

Strengths

• Includes data from 87 patients across two university medical centers
• Contains detailed outcome metrics like overall survival and progression-free survival ratios
• Covers a specific and rare tumor entity with limited available data

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count for the underlying data tables is unknown, which may limit suitability assessment
• The 88.4 KB file size suggests a limited scope, likely containing summary-level data rather than raw patient records

Provenance

Source

University Medical Center Freiburg and Technical University of Munich

Collection Method

Retrospective two-center analysis of patients discussed at Molecular Tumor Boards

Time Range

2019 to 2024

Freshness

Last updated 2026-05-20 11:55:13; freshness should be verified

Geography

Germany